Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

N ot all fortunes are created from the same starting point. This year, a small number of the 100 members of Forbes’ 2025 list ...

Investing.com -- Shares of MoonLake Immunotherapeutics soared 21.5% following reports that Merck (NSE: PROR) has engaged in discussions regarding a potential acquisition of the Swiss biotech firm for ...